Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1989
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1992 1
1993 2
1996 1
1997 3
2000 12
2001 37
2002 22
2003 18
2004 17
2005 25
2006 39
2007 59
2008 61
2009 72
2010 95
2011 86
2012 80
2013 111
2014 100
2015 121
2016 124
2017 132
2018 114
2019 107
2020 136
2021 147
2022 134
2023 166
2024 152
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

1,943 results

Results by year

Filters applied: . Clear all
Page 1
Breast cancer.
Harbeck N, Gnant M. Harbeck N, et al. Lancet. 2017 Mar 18;389(10074):1134-1150. doi: 10.1016/S0140-6736(16)31891-8. Epub 2016 Nov 17. Lancet. 2017. PMID: 27865536 Review.
Breast cancer is one of the three most common cancers worldwide. Early breast cancer is considered potentially curable. ...Primary conventional surgery is not the optimal choice for all patients any more. In triple-negative and HER2-positive early b …
Breast cancer is one of the three most common cancers worldwide. Early breast cancer is considered potentially curable. ...Pri …
Breast Cancer Treatment: A Review.
Waks AG, Winer EP. Waks AG, et al. JAMA. 2019 Jan 22;321(3):288-300. doi: 10.1001/jama.2018.19323. JAMA. 2019. PMID: 30667505 Review.
This review focuses on current approaches and evolving strategies for local and systemic therapy of breast cancer. OBSERVATIONS: Breast cancer is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone rec …
This review focuses on current approaches and evolving strategies for local and systemic therapy of breast cancer. OBSERVATIONS: B …
Molecular Classification of Breast Cancer.
Roy M, Fowler AM, Ulaner GA, Mahajan A. Roy M, et al. PET Clin. 2023 Oct;18(4):441-458. doi: 10.1016/j.cpet.2023.04.002. Epub 2023 May 31. PET Clin. 2023. PMID: 37268505 Review.
Breast carcinomas classified based on traditional morphologic assessment provide useful prognostic information. ...This article describes the association between the different molecular subtypes with the histologic subtypes of breast cancer and illustrates how these …
Breast carcinomas classified based on traditional morphologic assessment provide useful prognostic information. ...This article descr …
Treatment of breast cancer.
Maughan KL, Lutterbie MA, Ham PS. Maughan KL, et al. Am Fam Physician. 2010 Jun 1;81(11):1339-46. Am Fam Physician. 2010. PMID: 20521754 Free article. Review.
Stages I and II breast cancers are usually treated with breast-conserving surgery and radiation therapy. ...Choice of adjuvant systemic therapy depends on lymph node involvement, hormone receptor status, ERBB2 (formerly HER2 or HER2/neu) overexpression …
Stages I and II breast cancers are usually treated with breast-conserving surgery and radiation therapy. ...Choice of adjuvant …
Neoadjuvant treatment for HER2-positive breast cancer.
Takada M, Toi M. Takada M, et al. Chin Clin Oncol. 2020 Jun;9(3):32. doi: 10.21037/cco-20-123. Epub 2020 Jun 3. Chin Clin Oncol. 2020. PMID: 32527117 Free article. Review.
Neoadjuvant therapy has become a standard clinical practice to downsize the tumor and increase the breast-conserving rate. The addition of trastuzumab to neoadjuvant chemotherapy roughly doubles the proportion of patients with HER2-positive breast canc …
Neoadjuvant therapy has become a standard clinical practice to downsize the tumor and increase the breast-conserving rate. The additi …
Male breast cancer: an update.
Fox S, Speirs V, Shaaban AM. Fox S, et al. Virchows Arch. 2022 Jan;480(1):85-93. doi: 10.1007/s00428-021-03190-7. Epub 2021 Aug 30. Virchows Arch. 2022. PMID: 34458944 Review.
Male breast cancer (MBC) is rare, accounting for less than 1% of all breast cancer but the incidence has increased worldwide. ...BRCA2 carriers have 80 times the risk of the general population. Men generally present with breast cancer at an older age compared …
Male breast cancer (MBC) is rare, accounting for less than 1% of all breast cancer but the incidence has increased worldwide. …
HER2-Low Breast Cancer: a New Subtype?
Corti C, Giugliano F, Nicolò E, Tarantino P, Criscitiello C, Curigliano G. Corti C, et al. Curr Treat Options Oncol. 2023 May;24(5):468-478. doi: 10.1007/s11864-023-01068-1. Epub 2023 Mar 27. Curr Treat Options Oncol. 2023. PMID: 36971965 Review.
Breast cancer (BC) guidelines subdivide the disease into three main groups, namely hormone receptor (HR)-positive HER2-negative, HER2-positive, and triple-negative BC (TNBC). The natural history of the HER2-positive subtype has cha …
Breast cancer (BC) guidelines subdivide the disease into three main groups, namely hormone receptor (HR)-positive HER2- …
PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects.
Miricescu D, Totan A, Stanescu-Spinu II, Badoiu SC, Stefani C, Greabu M. Miricescu D, et al. Int J Mol Sci. 2020 Dec 26;22(1):173. doi: 10.3390/ijms22010173. Int J Mol Sci. 2020. PMID: 33375317 Free PMC article. Review.
Up to 40% of PIK3CA mutations are estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) -negative in primary and metastatic breast cancer. HER2 is overexpressed in 20-30% of breast cancers. HER1, HER2, HER3 a …
Up to 40% of PIK3CA mutations are estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) -negativ …
Immunotherapy in Breast Cancer.
Dvir K, Giordano S, Leone JP. Dvir K, et al. Int J Mol Sci. 2024 Jul 9;25(14):7517. doi: 10.3390/ijms25147517. Int J Mol Sci. 2024. PMID: 39062758 Free PMC article. Review.
Breast cancer has traditionally been considered an immunologically "cold" tumor, unresponsive to immunotherapy. However, clinical trials in recent years have found immunotherapy to be an efficacious therapeutic option for select patients. Breast cancer is categorize …
Breast cancer has traditionally been considered an immunologically "cold" tumor, unresponsive to immunotherapy. However, clinical tri …
Breast cancer during pregnancy: epidemiology, phenotypes, presentation during pregnancy and therapeutic modalities.
Boere I, Lok C, Poortmans P, Koppert L, Painter R, Vd Heuvel-Eibrink MM, Amant F. Boere I, et al. Best Pract Res Clin Obstet Gynaecol. 2022 Jun;82:46-59. doi: 10.1016/j.bpobgyn.2022.05.001. Epub 2022 May 9. Best Pract Res Clin Obstet Gynaecol. 2022. PMID: 35644793 Free article. Review.
MRI is appropriate to stage for distant disease on the indication. Breast cancer during pregnancy is less often hormone receptor-positive and more frequently triple-negative breast cancer compared to age-matched controls. ...Initiating cancer treatment during …
MRI is appropriate to stage for distant disease on the indication. Breast cancer during pregnancy is less often hormone receptor-p …
Cite
1,943 results